ArticleThe Analyst2026
Development of a surface enhanced Raman scattering lateral flow immunoassay with prolonged reproducibility and stability over time.
Article in The Analyst, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analysis of multiplexed SERS-based lateral flow assays: turning qualitative into quantitative for inflammatory bowel disease monitoring.The Analyst · 2026Article
- Matrix-Guided Size Selection of Plasmonic Nanoprobes for Improving Quantitative Robustness of SERS Lateral Flow Immunoassays.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lateral flow immunoassays (LFIAs) coupled to surface enhanced Raman scattering (SERS) measurements can produce quantitative outputs with excellent sensitivity. Despite this, they have not been adopted into point-of-care (POC) scenarios, due to the perceived lack of reproducibility and stability in SERS measurements over time. To address this, the performance, stability and reproducibility of a newly developed SERS-LFIA designed for the detection of liver injury has been assessed to investigate if the tests could yield the same results six-months after preparation. The SERS-LFIA incorporated silica coated Raman active gold nanoparticles to increase the stability when used with human serum samples and the SERS signals of the test and control lines were analysed using a handheld Raman reader to mimic its use at the POC. The relative standard deviations of key metrics, including reproducibility and variation in signal were assessed over the course of a 6 month stability study using a range of methods that aimed to standardise the output. Test line intensity, test/control ratio and slope linear regression outputs were all used to assess the SERS-LFIA results with the best reproducibility being achieved when normalising the test
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.